预后营养指数和修改格拉斯哥预后得分在晚期肺癌中具有可向突变的预后重要性
Burak Bilgin1, Yunus Kuralay2, Sebnem Yucel3
1Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Cankaya, 06800, Ankara, Turkey. drbbilgin@hotmail.com.
Journal of cancer research and clinical oncology
|April 26, 2024
概括
预后营养指数 (PNI) 和修改后的格拉斯哥预后得分 (mGPS) 预测了接受向治疗的晚期肺癌患者的结果. 在EGFR和ALK阳性亚组中,较高的PNI和较低的mGPS与较长的无进展生存期 (PFS) 相相关.
科学领域:
- 在瘤学瘤学.
- 生物标志物 生物标志物
- 临床研究 临床研究
背景情况:
- 炎症和营养状况显著影响癌症存活率.
- 预测营养指数 (PNI) 和修改后的格拉斯哥预测得分 (mGPS) 评估这些情况.
- 在接受向治疗的具有可向突变的晚期肺癌中,它们的预后价值需要评估.
研究的目的:
- 评估PNI和mGPS的预后意义.
- 为了评估它们在经过向治疗的EGFR突变或ALK重组的晚期肺癌患者中的实用性.
主要方法:
- 对182名患有EGFR突变或ALK重组的晚期肺癌患者进行了回顾性研究.
- 使用血清白蛋白和外围淋巴细胞计数计算PNI (值:50).
- 使用专蛋白和C反应蛋白 (CRP) 水平计算的mGPS (得分:0-2).
主要成果:
- 在EGFR (P=0.004) 和ALK (P=0.017) 分组中,高PNI患者的无进展生存时间 (PFS) 显着更长.
- 随着mGPS在EGFR (P<0.001) 和ALK (P=0.016) 分组中从0增加到2,PFS显著缩短.
结论:
- PNI和mGPS是可靠的预后指标.
- 这些指数是廉价且易于应用的.
- 它们是接受向治疗的具有可向突变的晚期肺癌患者的宝贵工具.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
